首页> 外文期刊>Advances in Interventional Cardiology: Postepy w Kardiologii Interwencyjnej >Morphological applicability of currently available stent grafts in the endovascular repair of asymptomatic abdominal aortic aneurysm in East-Central European patients
【24h】

Morphological applicability of currently available stent grafts in the endovascular repair of asymptomatic abdominal aortic aneurysm in East-Central European patients

机译:目前可用支架移植物的形态学适用性在东部欧洲患者的无症状腹主动脉瘤血管内修复中

获取原文
           

摘要

Introduction Currently, there is a?wide range of commercially available devices for endovascular aneurysm repair (EVAR) that differ in terms of both anatomical requirements and the technology and technique of deployment. Aim: To assess the applicability of currently commercially available devices for EVAR in the treatment of an asymptomatic abdominal aneurysm (AAA). Material and methods The study group included 100 patients with infrarenal AAA with a?maximum diameter ≥ 50 mm, qualified for invasive treatment at the University Hospital in 2013–2014. The aortoiliac morphological characteristics of the AAA were evaluated on preoperative computed tomography angiograms using the OsiriX DICOM viewer in the 3D-MPR mode. The morphological applicability of 14 types of CE-marked and FDA-approved stent grafts was determined based on their instructions for use (IFU). Results EVAR was feasible with at least one of the analysed devices in 68% of patients. The morphological applicability was as follows: Excluder Conformable (65%), Ovation iX (51%), Endurant II (47%), Treo (45%), Excluder C3 (45%), AFX 2 (45%), Incraft (44%), E-tegra (44%), Zenith Alfa (41%), Zenith Flex (40%), Anaconda (39%) Aorfix (37%), Altura (34%), and E-vita (20%). The differences in the stent graft applicability were statistically significant (p 0.001). A?wide diameter of the common iliac artery, angulated proximal neck, and diameter of proximal neck out of range constituted the most frequent causes of EVAR inapplicability. Conclusions The IFU-based applicability of currently available AAA stent graft systems differs significantly. Despite the constant evolution of EVAR technology, at least 32% of AAA will require a?different therapeutic approach.
机译:介绍目前,有一个?用于血管内动脉瘤修复(EVAR)的各种商业上可获得的装置,其既有解剖学要求和部署技术和技术。目的:评估目前商业上可获得的装置的适用性,用于治疗无症状腹部动脉瘤(AAA)。研究组包括100名患有1种Incraenal AAA患者的患者?最大直径≥50毫米,在2013 - 2014年在大学医院侵入治疗。在3D-MPR模式下使用Osirix DICom Viewer对术前计算断层扫描仪评估AAA的主动脉的形态特征。基于其使用说明(IFU)确定了14种CE标记和FDA批准的支架移植物的形态学适用性。结果EVAR可行于68%的患者中的至少一个分析的装置。形态学适用性如下:排除剂适形(65%),卵子IX(51%),耐培育II(47%),Treo(45%),排除剂C3(45%),AFX 2(45%),Incroft( 44%),E-Tegra(44%),Zenith Alfa(41%),Zenith Flex(40%),Anaconda(39%)Aorfix(37%),阿尔图拉(34%)和E-VITA(20%) )。支架移植物适用性的差异是统计学上显着的(P <0.001)。 α宽直径的髂髂动脉,角度近端颈部和近端颈部直径超出范围,构成了EVAR惰性的最常见的原因。结论目前可用AAA支架移植系统的IFU的适用性显着不同。尽管Evar技术的持续发展,但至少32%的AAA需要一个不同的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号